Barclays Maintains Overweight on Macrogenics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Macrogenics (NASDAQ:MGNX) and raises the price target from $23 to $25.
March 08, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Macrogenics and raises the price target from $23 to $25.
The upgrade in price target by a reputable analyst like Peter Lawson from Barclays indicates a positive outlook on Macrogenics, suggesting confidence in the company's future performance. This is likely to instill investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100